Sharon Vered Email

VP CMC . NeuroSense Therapeutics

Current Roles

Employees:
34
Revenue:
$5.3M
About
Advancing research, development and therapy for ALS and additional CNS indications.\n\nNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the development of a ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases.\n\nCurrently in conducting a Phase 2b, double-blind, randomized, placebo controlled clinical study in ALS patients globally.\n$NRSN
NeuroSense Therapeutics Address

Cambridge, MA
IL
NeuroSense Therapeutics Email